FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting P Price Ben Gil	2. Issuer Name <b>and</b> Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) C/O REXAHN PHARMACEU INC., 15245 SHADY GROVE 455	/	3. Date of Earliest Transaction (Month/Day/Year) 01/29/2019				Officer (give title below)	Other (specify b	below)		
(Street) ROCKVILLE, MD 20850	4. If Amendment,	Date Orig	inal I	Filed(Mont	h/Day/Y	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	ction	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership
		(Monul/Day/Tear)	Code	v	Amount	(A) or (D)	Price	(instr. 5 and 4)	or Indirect (I) (Instr. 4)	· ·
Common Stock	01/29/2019		Р		15,000		\$ 0.6094 <u>(1)</u>	15,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless SEC 1474 (9the form displays a currently valid OMB control number.

02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, caus, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.	5	5. Nur	nber	6. Date Exer	rcisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	n o	of		and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	Ε	Deriva	ative	(Month/Day	/Year)	Unde	rlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	S	Securi	ties			Secu	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative				Α	Acqui	red			(Instr	. 3 and		Owned	Security:	(Instr. 4)
	Security				(.	A) or				4)			Following	Direct (D)	
						Dispo							· F · · · · ·	or Indirect	
						of (D)							Transaction(s)	< /	
					`	Instr.							(Instr. 4)	(Instr. 4)	
					4	l, and	5)								
											Amount				
								Date	Evaluation		or				
								Exercisable	Expiration Date	Title	Number				
								Exercisable	Date		of				
				Code V	/ (	(A)	(D)				Shares				

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Price Ben Gil C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	х						

## **Signatures**

/s/ Douglas J. Swirsky, as attorney-in-fact for Ben Gil Price	01/31/2019	
Signature of Reporting Person	Date	

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price of \$0.6094 per share represents a weighted average of purchase prices ranging from \$0.6016 to \$0.6100 per share. The reporting person undertakes to provide (1) upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.